With regard to the latter point, combinations therapies based on the co-administration of semaglutide (or tirzepatide) and amylin analogs may offer, as compared to GLP-1 RA or dual GIP/GLP-1 RA monotherapies, greater glycemic improvements and weight loss reductions in patients with autoimmune diabetes and comorbid overweight/obesity. Here, GIP is linked to obesity disorder.